STI571治疗BCR/ABL融合基因阳性白血病观察

Study on BCR/ABL-positive leukemia treated with STI571

目的 :观察酪氨酸激酶抑制剂STI5 71在BCR/ABL融合基因阳性表达白血病的治疗效果和副作用。方法 :已确诊BCR/ABL+ 的 8例慢性粒细胞性白血病 (CML)和 1例急性淋巴细胞白血病 (ALL)患者采用STI5 71+Ara -C治疗。结果 :2例CML -慢性期患者均CR至今 ,6例CML -急粒变患者有 2例CR ,其中 1例CR至今已 3 7周 ,1例ALL在第三次血液学CR后经治疗维持CR2 8周后复发。结论 :STI5 71可诱导BCR/ABL+ 白血病患者完全缓解 ,降低骨髓BCR/ABL+ 白血病细胞 ,延长CR期 ,药物副作用轻微易耐受 。

Objective To observe the effect and side effects of STI571,an tyrosine kinase inhibitor,on BCR/ABL positive leukemia. Methods 9 cases of BCR/ABL-positive chronic myeloid leukemia and acute lymphoblastic leukemia were treated with STI571+Ara-C, and continued the treatment with STI571 after complete remission(CR). Results 2 cases of chronic myeloid leukemia-chronic phase had CR and are still in CR now, 2 of 6 cases with myeloid blastic crisis had CR, and 1of them remain in CR for 37 weeks. 1 patient of acute lymphoblastic leukemia relapsed when remain in CR for 28 weeks after starting the treatment in the third CR period. Conclusion STI571 can induce CR of BCR/ABL-positive-leukemia,decrease BCR/ABL-positive-leukemia cells,prolong the period of CR, the adverse effects are slight,the individual variation of the treatment is obviously.